|
|
Profile
|
Delegates :
Junichi Hosokawa |
|
Incorporated :
October 11 , 2024 |
Paid in Capital :
5 Million yen |
Employees :
1 人 |
Address :
Room 307, Chiba University Inohana Innovation Plaza, 1-8-15 Inohana, Chuo-ku, Chiba City, CHIBA
〒260-0856
|
TEL/FAX :
/ |
URL：
https://generize.co.jp/en/ |
Attachment :
 Generize_Pamphlet_EN.pdf [ 799.9KiB ] |
Mission/Background :
Generize Co., Ltd. is a genetic testing company dedicated to supporting patients with rare and hereditary diseases. Under the philosophy of “Saving more patients and leaving no one behind,” the company aims to provide fast, simple, and highly accurate genetic testing services. Generize is a registered clinical laboratory in Chiba Prefecture (Registration No. 28, June 2025) and began accepting testing orders in October 2025. By leveraging proprietary genomic analysis technologies, Generize seeks to become a global infrastructure provider of genetic diagnostics for patients worldwide. |
|
Technology & Business
|
Generize provides NGS-based genetic testing services for rare diseases, hereditary cancers, and other genetic disorders. Its proprietary bioinformatics pipeline enables analysis of difficult genomic regions, including genes with homologous regions, CNVs, deep intronic variants, and founder mutations. The company offers gene panel testing, single-gene testing, exome analysis, and genomic consultation services for healthcare and research institutions.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Rare Disease Gene Panel Test
|
Service/Marketing
|
Diagnostic gene panels (1-50 genes) for designated intractable diseases
|
Expand adoption by healthcare institutions
|
Hereditary Cancer Panel Test
|
Service/Marketing
|
Genetic testing for hereditary cancer syndromes
|
Increase customer base
|
Single Gene Test
|
Service/Marketing
|
Single-gene testing for carrier screening of relatives and confirmation of germline variants
|
Expand testing menu
|
Research Exome Analysis
|
Service/Marketing
|
Exome sequencing and variant analysis for research use
|
Strengthen research collaborations
|
Genomic Analysis Service
|
Service/Marketing
|
Bioinformatics and NGS data analysis service
|
Accelerate overseas expansion
|
|
Highlights
|
Generize achieved 100% variant detection accuracy and 100% specificity with a “Good” overall rating in the CAP proficiency test for NGS analysis. The company was also selected as a grant recipient of the Himawari Venture Development Fund, and was accepted into C-GATE, an overseas business expansion training program run by Chiba City.
|
|
Alliance strategy
|
Generize seeks collaborative partnerships with hospitals, academic institutions, and biotechnology companies working in rare and hereditary diseases. The company is also interested in international business partnerships, distribution alliances, and joint research opportunities to expand access to advanced genetic diagnostics.
|
|
|